

Proteomedix announces grant of U.S. patent on Proclarix®.

Zurich-Schlieren, Switzerland, July 05, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, is pleased to announce that the United States Patent and Trademark Office granted to the company U.S. Patent No. [11,320,435](#), titled “Method of detecting proteins in human samples and uses of such methods” that covers Proteomedix’ lead product [Proclarix®](#).

“We are extremely pleased about the grant of this patent in the U.S. as it further validates the potential of Proclarix®, strengthens our intellectual property position, and highlights our commitment to innovation of biomarkers for prostate cancer diagnosis and prognosis,” said Ralph Schiess, CSO and co-founder of Proteomedix.

The granted patent demonstrates the company’s strong intellectual property position in protein biomarker technology in the US (in addition to other markets), and complements the existing patent portfolio covering the method and cancer-specific biomarkers that is also granted across multiple markets.

The [granted patents](#) and [published studies](#) further validate the potential of Proclarix® and support the company’s ongoing investigator-led observational studies evaluating the impact of the IVD-test on improving prostate cancer diagnosis and patient management.

About Proclarix®

[Proclarix®](#) is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining *in-vitro* assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer. Proclarix is currently not available in the U.S.

About Proteomedix

[Proteomedix](#) is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.

For further details, please contact:

Dr. Ralph Schiess, CSO

schiess@proteomedix.com, +41 44 733 40 90